Status:
UNKNOWN
Clinical Concordance Study Between Watson for Oncology and Clinician Practice
Lead Sponsor:
Qingdao University
Conditions:
Cancer
Artificial Intelligence
Eligibility:
All Genders
18-90 years
Brief Summary
At present, Watson for Oncology has been applied in 14 countries worldwide, including China, the United States, Holland, Thailand, India, Korea, Poland, Slovakia and Bangladesh. In a double-blind stud...
Detailed Description
This study was approved by the Affiliated Hospital of Qingdao University ethics committee.The investigators would randomly selected cancer patients, including lung cancer, breast cancer, gastric cance...
Eligibility Criteria
Inclusion
- a histology of lung cancer,breast cancer,gastric cancer, colon cancer， rectal cancer，cervical cancer and ovarian cancer
- had no prior systemic therapy and need neoadjuvant/adjuvant or metastatic therapy
- had prior neoadjuvant therapy, adjuvant therapy and/or surgery and are now metastatic
- have had prior surgery and now need adjuvant therapy
- seeking an additional therapy whose cancer has progressed beyond its initial metastatic therapy (second line)
Exclusion
- not have confirmed diagnoses of invasive cancer
- under 18 years of age
- pregnant
- with multiple concurrent primary cancers or a local recurrence or a new primary at the same site of a previously treated cancer
Key Trial Info
Start Date :
April 12 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2019
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT03400514
Start Date
April 12 2017
End Date
January 31 2019
Last Update
January 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China